Ayşe Dilvin Mansır Elmalı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ayşe Dilvin Mansır Elmalı has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Fuat Erel
Department of Pulmonology, Faculty of Medicine, Balıkesir University, 10145 Balıkesir, Türkiye
1 shared publication - Gulcin Yilmaz Gunes
Department of Pulmonology, Faculty of Medicine, Balikesir University, 10145 Balikesir, Türkiye
1 shared publication - Hikmet Çoban
Department of Pulmonology, Faculty of Medicine, Balıkesir University, 10145 Balıkesir, Türkiye
1 shared publication - Merve Akış Yılmaz
Department of Medical Biochemistry, Faculty of Medicine, Balıkesir University, 10145 Balıkesir, Türkiye
1 shared publication - Merve Yumrukuz Şenel
Department of Chest Diseases, Faculty of Medicine, Balıkesir University, Balıkesir, Türkiye
1 shared publication - Mustafa Çolak
Department of Pulmonology, Faculty of Medicine, Balıkesir University, 10145 Balıkesir, Türkiye
1 shared publication
Latest Publications
- Open Access
Could Hepcidin Be a Phenotype-Related Biomarker in Patients with Stable Bronchiectasis?
Hepcidin centrally regulates iron homeostasis and responds to inflammation, iron status, hypoxia, and erythropoietic signaling, yet circulating hepcidin in stable bronchiectasis is poorly characterized. We compared serum hepcidin between 61 patients with stable bronchiectasis and 39 controls without bronchiectasis and assessed associations with anemia, iron metabolism, systemic inflammation, severity, and phenotype. Hepcidin was lower in bronchiectasis (20.34 ± 7.85 vs. 28.34 ± 9.82 ng/mL; median, 20.31 [15.07–25.35] vs. 25.03 [21.00–34.66] ng/mL; p < 0.001). It showed no significant associations with anemia status or hematologic, iron metabolism, erythropoietic, or inflammatory indices. Exploratory analyses identified phenotype differences (p = 0.002); levels were lowest in chronic obstructive pulmonary disease–bronchiectasis (15.98 ± 6.52 ng/mL), compared with bronchiectasis alone (21.57 ± 6.71) and asthma–bronchiectasis (24.81 ± 9.00). Low hepcidin discriminated bronchiectasis from controls (AUC = 0.729; 95% bootstrap CI: 0.628–0.822); the ≤20.85 ng/mL cutoff yielded 59.0% sensitivity and 79.5% specificity. To our knowledge, this is the first human case–control evidence of reduced circulating hepcidin in stable bronchiectasis. The absence of significant associations with systemic inflammation or anemia/iron status, alongside phenotype differences, suggests that hepcidin may be a candidate biomarker of biological heterogeneity in bronchiectasis not reflected by routine markers.
Open AccessCould Hepcidin Be a Phenotype-Related Biomarker in Patients with Stable Bronchiectasis?
Hepcidin centrally regulates iron homeostasis and responds to inflammation, iron status, hypoxia, and erythropoietic signaling, yet circulating hepcidin in stable bronchiectasis is poorly characterized. We compared serum hepcidin between 61 patients with stable bronchiectasis and 39 controls without bronchiectasis and assessed associations with anemia, iron metabolism, systemic inflammation, severity, and phenotype. Hepcidin was lower in bronchiectasis (20.34 ± 7.85 vs. 28.34 ± 9.82 ng/mL; median, 20.31 [15.07–25.35] vs. 25.03 [21.00–34.66] ng/mL; p < 0.001). It showed no significant associations with anemia status or hematologic, iron metabolism, erythropoietic, or inflammatory indices. Exploratory analyses identified phenotype differences (p = 0.002); levels were lowest in chronic obstructive pulmonary disease–bronchiectasis (15.98 ± 6.52 ng/mL), compared with bronchiectasis alone (21.57 ± 6.71) and asthma–bronchiectasis (24.81 ± 9.00). Low hepcidin discriminated bronchiectasis from controls (AUC = 0.729; 95% bootstrap CI: 0.628–0.822); the ≤20.85 ng/mL cutoff yielded 59.0% sensitivity and 79.5% specificity. To our knowledge, this is the first human case–control evidence of reduced circulating hepcidin in stable bronchiectasis. The absence of significant associations with systemic inflammation or anemia/iron status, alongside phenotype differences, suggests that hepcidin may be a candidate biomarker of biological heterogeneity in bronchiectasis not reflected by routine markers.